No Data
No Data
TYK Medicines Logs Wider Attributable Loss in H1
Same source Kang pharmaceuticals-B (02410.HK) R&D costs for the first half of the year were 0.138 billion yuan, an increase of 15.3% compared to the same period last year.
Guolonghui, August 30th, Tongyuan-Kang Pharmaceutical-B (02410.HK) announced that for the six months ended June 30, 2024 and 2023, the Group did not generate any revenue. R&D costs for the period amounted to RMB 137,758,000, an increase of 15.3% year-on-year. This increase was mainly attributed to an increase in experimental and testing expenses, especially those related to the development of core products. The loss for the reporting period increased by 26.3% from RMB 173,849,000 for the six months ended June 30, 2023 to RMB XXX for the six months ended June 30, 2024.
Express News | Tyk Medicines Inc - Hy Loss Attributable RMB219.1 Mln
TYK MEDICINES-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
Hong Kong stock market news: 同源康医药-B(02410) surges over 18% to reach a new high, with a 90% increase compared to the IPO price. The total market value exceeds 8 billion Hong Kong dollars.
Tongyuan Kangyiyao-B (02410) rose more than 18%, reaching a high of HK$23.1, setting a new record since its listing, with an increase of over 90% compared to its IPO price of HK$12.1. As of the time of writing, the stock is up 15.27%, trading at HK$22.5, with a turnover of HK$6.147 million.
Hong Kong stocks surged | Same Source Kang Medicine-B (02410) rose more than 22% on the second day of listing, nearly 40% higher than the IPO price, focusing on the field of cancer treatment.
The next day after the listing, Tongyuan Kang Medical-B (02410) rose more than 22%, reaching a high of HKD 16.82, an increase of more than 39% compared to the IPO price of HKD 12.1. As of the time of writing, it has risen by 20.58% to HKD 16.52, with a turnover of HKD 8.8934 million.
No Data